A practical reference on Dihexa: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-01. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
== Medical uses == People diagnosed with trypanosome-caused disease should be treated with an anti-trypanosomal. Treatment is based on stage, 1 or 2, and parasite, T. b. rhodesiense or T. b. gambiense. In stage 1 disease, trypanosomes are present only in the peripheral circulation. In stage 2 disease, trypanosomes have crossed the blood-brain barrier and are present in the central nervous system. The following are considerable treatment options: Melarsoprol is a treatment used during the second stage of the disease. So far, it is the only treatment available for late-stage T. b. rhodesiense. Due to high toxicity, melarsoprol is reserved only for the most dangerous cases. Other agents associated with lower toxicity levels are used during stage 1 of the disease. The approval of the nifurtimox-eflornithine combination therapy (NECT) in 2009 for the treatment of T. b. gambiense limited the use of melarsoprol to the treatment of second-stage T. b. rhodesiense. Failure rates of 27% in certain African countries have been reported. This was caused by both drug resistance and additional mechanisms that have not yet been elucidated. Resistance is likely due to transport problems associated with the P2 transporter, an adenine-adenosine transporter. Resistance can occur with point mutations within this transporter. Resistance has been present since the 1970s. In August 2024, the World Health Organization recommended fexinidazole, developed by the Drugs for Neglected Diseases initiative and partners to replace melarsoprol as the first-line treatment for sleeping sickness caused by T.
The effects included brightened colors, increased visual contrast, open-eye visuals like colors and patterns, pareidolia, increased significance of objects, enhanced music appreciation, feeling intoxicated, self-analysis, insights, increased body awareness, feelings of joy, happiness, and peacefulness, feeling hyper and energized, feelings of empathy, things feeling ridiculous, humor and laughter, religious feelings, restlessness, social discomfort and avoidance, and nausea, among others. Mescaline was one of Shulgin's "magical half-dozen" psychedelic drugs in PiHKAL. Prominence of color with mescaline is distinctive, appearing brilliant and intense. Recurring visual patterns observed during the mescaline experience include stripes, checkerboards, angular spikes, multicolor dots, and very simple fractals that can turn very complex. The English writer Aldous Huxley described these self-transforming amorphous shapes as like animated stained glass illuminated from light coming through the eyelids in his autobiographical book The Doors of Perception (1954). Like LSD, mescaline induces distortions of form and kaleidoscopic experiences but they manifest more clearly with eyes closed and under low lighting conditions. Heinrich Klüver coined the term "cobweb figure" in the 1920s to describe one of the four form constant geometric visual hallucinations experienced in the early stage of a mescaline trip: "Colored threads running together in a revolving center, the whole similar to a cobweb". The other three are the chessboard design, tunnel, and spiral.
=== 2-D liquid chromatography === By coupling liquid chromatography with a variety of other immunodetection techniques such as serological proteome analysis (SERPA), it is possible to analyze the hydrophobicity, PI, relative mass, and antibody reactivity of antibodies within a given serum.
Sources: en.wikipedia.org
=== Cell culture === One of the key advantages of droplet-based microfluidics is the ability to use droplets as incubators for single cells. In addition, droplets can be applied for studies on embryogenesis of animals and plants. Devices capable of generating thousands of droplets per second open new ways to characterize cell populations, not only based on a specific marker measured at a specific time point but also based on cells' kinetic behavior such as protein secretion, enzyme activity or proliferation. Recently, a method was found to generate a stationary array of microscopic droplets for single-cell incubation that does not require the use of a surfactant.
The definitions of VOCs used for control of precursors of photochemical smog used by the U.S. Environmental Protection Agency (EPA) and state agencies in the US with independent outdoor air pollution regulations include exemptions for VOCs that are determined to be non-reactive, or of low-reactivity in the smog formation process. Prominent is the VOC regulation issued by the South Coast Air Quality Management District in California and by the California Air Resources Board (CARB). However, this specific use of the term VOCs can be misleading, especially when applied to indoor air quality because many chemicals that are not regulated as outdoor air pollution can still be important for indoor air pollution. Following a public hearing in September 1995, California's ARB uses the term "reactive organic gases" (ROG) to measure organic gases. The CARB revised the definition of "Volatile Organic Compounds" used in their consumer products regulations, based on the committee's findings. In addition to drinking water, VOCs are regulated in pollutant discharges to surface waters (both directly and via sewage treatment plants) as hazardous waste, but not in non-industrial indoor air. The Occupational Safety and Health Administration (OSHA) regulates VOC exposure in the workplace. Volatile organic compounds that are classified as hazardous materials are regulated by the Pipeline and Hazardous Materials Safety Administration while being transported.
Thermodynamics is concerned with heat and temperature and their relation to energy and work. It defines macroscopic variables, such as internal energy, entropy, and pressure, that partly describe a body of matter or radiation. It states that the behavior of those variables is subject to general constraints common to all materials. These general constraints are expressed in the four laws of thermodynamics. Thermodynamics describes the bulk behavior of the body, not the microscopic behaviors of the very large numbers of its microscopic constituents, such as molecules. The behavior of these microscopic particles is described by, and the laws of thermodynamics are derived from, statistical mechanics. The study of thermodynamics is fundamental to materials science. It forms the foundation to treat general phenomena in materials science and engineering, including chemical reactions, magnetism, polarizability, and elasticity. It explains fundamental tools such as phase diagrams and concepts such as phase equilibrium.
Sources: en.wikipedia.org
By 1902, sales made up 5 percent of the company's profits, and "heroinism" had attracted media attention. Oxycodone, a thebaine derivative similar to codeine, was introduced by Bayer in 1916 and promoted as a less-addictive analgesic. Preparations of the drug such as oxycodone with paracetamol and extended release oxycodone remain popular to this day. A range of synthetic opioids such as methadone (1937), pethidine (1939), fentanyl (late 1950s), and derivatives thereof have been introduced, and each is preferred for certain specialized applications. Nonetheless, morphine remains the drug of choice for American combat medics, who carry packs of syrettes containing 16 milligrams each for use on severely wounded soldiers. No drug has been found that can match the painkilling effect of opioids without also duplicating much of their addictive potential.
The armed forces of Brazil are the largest in Latin America by active personnel and the largest in terms of military equipment. It consists of the Brazilian Army (including the Army Aviation Command), the Brazilian Navy (including the Marine Corps and Naval Aviation) and the Brazilian Air Force. Brazil's conscription policy gives it one of the world's largest military forces, estimated at more than 1.6 million reservists annually. The Air Force is the largest in Latin America and has about 700 crewed aircraft in service and effective about 67,000 personnel. Numbering close to 236,000 active personnel, the Brazilian Army has the largest number of armored vehicles in South America, including armored transports and tanks. The states' Military Police and the Military Firefighters Corps are designated as auxiliary forces of the army by the constitution, but are under the control of each state's governor. Brazil's navy once operated some of the most powerful warships in the world with the two Minas Geraes-class dreadnoughts, sparking a naval arms race between Argentina, Brazil, and Chile. Today, it is a green water force and has a group of specialized elite in retaking ships and naval facilities, GRUMEC, unit specially trained to protect Brazilian oil platforms along its coast. As of 2022, it is the only navy in Latin America that operates a helicopter carrier, NAM Atlântico and one of twelve navies in the world to operate or have one under construction.
=== Brazil === The rate of overweight and obesity in Brazilian children increased from 4% in the 1980s to 14% in the 1990s. In 2007 the prevalence of children overweight and childhood obesity was 11.1% and 2.7% in girls, 8.2% and 1.5% in boys, respectively.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.